.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AH04_Naloxone.Naloxone_2 .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AH04_Naloxone.Naloxone_2| name: | Naloxone_2 |
| ATC code: | A06AH04_2 | route: | nasal |
| n-compartments | 2 |
Naloxone is an opioid antagonist used primarily to rapidly reverse opioid overdose. It binds to opioid receptors and can reverse and block the effects of other opioids, including respiratory depression, sedation, and hypotension. Naloxone is approved and widely used today both in emergency settings and by bystanders.
Pharmacokinetic parameters after nasal administration in healthy adults.
Saari, TI, et al., & Dale, O (2024). Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. Clinical pharmacokinetics 63(4) 397–422. DOI:10.1007/s40262-024-01355-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38485851
Robinson, A, & Wermeling, DP (2014). Intranasal naloxone administration for treatment of opioid overdose. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 71(24) 2129–2135. DOI:10.2146/ajhp130798 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25465584
Malmros Olsson, E, et al., & Lundeberg, S (2021). Rapid systemic uptake of naloxone after intranasal administration in children. Paediatric anaesthesia 31(6) 631–636. DOI:10.1111/pan.14175 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33687794